ambroxol has been researched along with Parkinson Disease in 16 studies
Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The ambroxol therapy was well tolerated, with no serious adverse events." | 6.94 | Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. ( Cable, S; Campbell, P; D'Souza, G; Elflein, J; Foltynie, T; Hällqvist, J; Hehir, J; Heywood, WE; Hosking, J; Khengar, R; Lee, K; Libri, V; Limousin, P; Mills, K; Mullin, S; Schapira, AHV; Smith, L; Streeter, A; Toffoli, M; Woodgate, P; Zetterberg, H, 2020) |
| "Ambroxol is a pharmacological chaperone for GCase and is able to raise the levels of GCase and could therefore be a disease-modifying treatment for PDD." | 6.90 | Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. ( Bartha, R; Borrie, M; Coleman, K; Finger, E; Hegele, RA; Jenkins, ME; Jog, M; Li, Z; MacDonald, P; MacKinley, J; Mahuran, D; Morrow, SA; Pasternak, SH; Rupar, CA; Silveira, CRA; Tirona, RG; Wells, J; Zou, G, 2019) |
| "Both patients with non-neuronopathic Gaucher disease (GD) and heterozygous GBA mutation carrier are at increased risk for Parkinson disease (PD)." | 6.58 | Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development. ( Arkadir, D; Dinur, T; Ilan, Y; Ishay, Y; Szer, J; Zimran, A, 2018) |
| "Ambroxol hydrochloride is an oral mucolytic drug available over-the-counter for many years as cough medicine." | 5.62 | Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data. ( Al-Hertani, W; Becker-Cohen, M; Castillo-Garcia, D; Ceron-Rodriguez, M; Chan, A; Dinur, T; Fiumara, A; Istaiti, M; Kiec-Wilk, B; Lee, BH; Ramaswami, U; Revel-Vilk, S; Rodic, P; Rubio, B; Tincheva, RS; Yang, CF; Zimran, A, 2021) |
| "Ambroxol treatment significantly reduced HexSph concentration in GD (by 2." | 5.62 | Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism. ( Baydakova, GV; Bezrukikh, VA; Bogdanova, DA; Bolshakova, OI; Cheblokov, AA; Emelyanov, AK; Kopytova, AE; Miliukhina, IV; Nikolaev, MA; Pchelina, SN; Rychkov, GN; Salogub, GN; Sarantseva, SV; Senkevich, KA; Usenko, TC; Zakharova, EY, 2021) |
| "Treatment with ambroxol hydrochloride increased glucosylceramidase activity in fibroblasts from healthy controls, Gaucher disease and heterozygous glucocerebrosidase mutation carriers with and without Parkinson's disease." | 5.40 | Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. ( Abramov, AY; Chau, KY; Cooper, JM; Foltynie, T; Gegg, M; Hughes, D; Magalhaes, J; McNeill, A; Mehta, A; Schapira, AH; Shen, C, 2014) |
| " The literature review of the usage of ambroxol acting as a pharmacological chaperone for beta-glucocerebrosidase in Gaucher disease and Parkinson’s disease associated with GBA variants has been reviewed." | 5.22 | Pharmacological chaperone therapy for the treatment of inborn errors of metabolism ( Jezela-Stanek, A; Lipiński, P; Tylki-Szymańska, A, 2022) |
| "Our work supports the proposition that ambroxol should be further investigated as a potential novel disease-modifying therapy for treatment of Parkinson disease and neuronopathic Gaucher disease to increase glucocerebrosidase activity and decrease α-synuclein and phosphorylated α-synuclein protein levels." | 3.83 | Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice. ( Bezard, E; Daly, L; Migdalska-Richards, A; Schapira, AH, 2016) |
| "The ambroxol therapy was well tolerated, with no serious adverse events." | 2.94 | Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. ( Cable, S; Campbell, P; D'Souza, G; Elflein, J; Foltynie, T; Hällqvist, J; Hehir, J; Heywood, WE; Hosking, J; Khengar, R; Lee, K; Libri, V; Limousin, P; Mills, K; Mullin, S; Schapira, AHV; Smith, L; Streeter, A; Toffoli, M; Woodgate, P; Zetterberg, H, 2020) |
| "Ambroxol is a pharmacological chaperone for GCase and is able to raise the levels of GCase and could therefore be a disease-modifying treatment for PDD." | 2.90 | Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. ( Bartha, R; Borrie, M; Coleman, K; Finger, E; Hegele, RA; Jenkins, ME; Jog, M; Li, Z; MacDonald, P; MacKinley, J; Mahuran, D; Morrow, SA; Pasternak, SH; Rupar, CA; Silveira, CRA; Tirona, RG; Wells, J; Zou, G, 2019) |
| "Both patients with non-neuronopathic Gaucher disease (GD) and heterozygous GBA mutation carrier are at increased risk for Parkinson disease (PD)." | 2.58 | Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development. ( Arkadir, D; Dinur, T; Ilan, Y; Ishay, Y; Szer, J; Zimran, A, 2018) |
| "Ambroxol hydrochloride is an oral mucolytic drug available over-the-counter for many years as cough medicine." | 1.62 | Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data. ( Al-Hertani, W; Becker-Cohen, M; Castillo-Garcia, D; Ceron-Rodriguez, M; Chan, A; Dinur, T; Fiumara, A; Istaiti, M; Kiec-Wilk, B; Lee, BH; Ramaswami, U; Revel-Vilk, S; Rodic, P; Rubio, B; Tincheva, RS; Yang, CF; Zimran, A, 2021) |
| "Ambroxol treatment significantly reduced HexSph concentration in GD (by 2." | 1.62 | Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism. ( Baydakova, GV; Bezrukikh, VA; Bogdanova, DA; Bolshakova, OI; Cheblokov, AA; Emelyanov, AK; Kopytova, AE; Miliukhina, IV; Nikolaev, MA; Pchelina, SN; Rychkov, GN; Salogub, GN; Sarantseva, SV; Senkevich, KA; Usenko, TC; Zakharova, EY, 2021) |
| "Treatment with ambroxol hydrochloride increased glucosylceramidase activity in fibroblasts from healthy controls, Gaucher disease and heterozygous glucocerebrosidase mutation carriers with and without Parkinson's disease." | 1.40 | Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. ( Abramov, AY; Chau, KY; Cooper, JM; Foltynie, T; Gegg, M; Hughes, D; Magalhaes, J; McNeill, A; Mehta, A; Schapira, AH; Shen, C, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 7 (43.75) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, SY | 2 |
| Taanman, JW | 2 |
| Gegg, M | 2 |
| Schapira, AHV | 3 |
| Tripathi, P | 1 |
| Ganeshpurkar, A | 1 |
| Singh, SK | 1 |
| Krishnamurthy, S | 1 |
| Lipiński, P | 1 |
| Jezela-Stanek, A | 1 |
| Tylki-Szymańska, A | 1 |
| Mullin, S | 1 |
| Smith, L | 1 |
| Lee, K | 1 |
| D'Souza, G | 1 |
| Woodgate, P | 1 |
| Elflein, J | 1 |
| Hällqvist, J | 1 |
| Toffoli, M | 1 |
| Streeter, A | 1 |
| Hosking, J | 1 |
| Heywood, WE | 1 |
| Khengar, R | 1 |
| Campbell, P | 1 |
| Hehir, J | 1 |
| Cable, S | 1 |
| Mills, K | 1 |
| Zetterberg, H | 1 |
| Limousin, P | 1 |
| Libri, V | 1 |
| Foltynie, T | 2 |
| Schneider, SA | 1 |
| Alcalay, RN | 1 |
| Istaiti, M | 1 |
| Revel-Vilk, S | 1 |
| Becker-Cohen, M | 1 |
| Dinur, T | 2 |
| Ramaswami, U | 1 |
| Castillo-Garcia, D | 1 |
| Ceron-Rodriguez, M | 1 |
| Chan, A | 1 |
| Rodic, P | 1 |
| Tincheva, RS | 1 |
| Al-Hertani, W | 1 |
| Lee, BH | 1 |
| Yang, CF | 1 |
| Kiec-Wilk, B | 1 |
| Fiumara, A | 1 |
| Rubio, B | 1 |
| Zimran, A | 2 |
| Kopytova, AE | 1 |
| Rychkov, GN | 1 |
| Nikolaev, MA | 1 |
| Baydakova, GV | 1 |
| Cheblokov, AA | 1 |
| Senkevich, KA | 1 |
| Bogdanova, DA | 1 |
| Bolshakova, OI | 1 |
| Miliukhina, IV | 1 |
| Bezrukikh, VA | 1 |
| Salogub, GN | 1 |
| Sarantseva, SV | 1 |
| Usenko, TC | 1 |
| Zakharova, EY | 1 |
| Emelyanov, AK | 1 |
| Pchelina, SN | 1 |
| Silveira, CRA | 1 |
| MacKinley, J | 1 |
| Coleman, K | 1 |
| Li, Z | 1 |
| Finger, E | 1 |
| Bartha, R | 1 |
| Morrow, SA | 1 |
| Wells, J | 1 |
| Borrie, M | 1 |
| Tirona, RG | 1 |
| Rupar, CA | 1 |
| Zou, G | 1 |
| Hegele, RA | 1 |
| Mahuran, D | 1 |
| MacDonald, P | 1 |
| Jenkins, ME | 1 |
| Jog, M | 1 |
| Pasternak, SH | 1 |
| McNeill, A | 1 |
| Magalhaes, J | 1 |
| Shen, C | 1 |
| Chau, KY | 3 |
| Hughes, D | 1 |
| Mehta, A | 1 |
| Cooper, JM | 1 |
| Abramov, AY | 1 |
| Schapira, AH | 3 |
| Albin, RL | 1 |
| Dauer, WT | 1 |
| Ambrosi, G | 1 |
| Ghezzi, C | 1 |
| Zangaglia, R | 1 |
| Levandis, G | 1 |
| Pacchetti, C | 1 |
| Blandini, F | 1 |
| Maor, G | 1 |
| Cabasso, O | 1 |
| Krivoruk, O | 1 |
| Rodriguez, J | 1 |
| Steller, H | 1 |
| Segal, D | 1 |
| Horowitz, M | 1 |
| Sanchez-Martinez, A | 1 |
| Beavan, M | 2 |
| Gegg, ME | 1 |
| Whitworth, AJ | 1 |
| Migdalska-Richards, A | 1 |
| Daly, L | 1 |
| Bezard, E | 1 |
| Ishay, Y | 1 |
| Szer, J | 1 |
| Ilan, Y | 1 |
| Arkadir, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients With Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease[NCT02941822] | Phase 2 | 23 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| Ambroxol as a Disease-modifying Treatment to Reduce the Risk of Cognitive Impairment in GBA-associated Parkinson's Disease. A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial[NCT05287503] | Phase 2 | 65 participants (Actual) | Interventional | 2022-02-15 | Active, not recruiting | ||
| Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia[NCT04405596] | Phase 1/Phase 2 | 15 participants (Anticipated) | Interventional | 2025-01-31 | Not yet recruiting | ||
| Effect of Ambroxol on the Inflammatory Markers and Clinical Outcome of Patients With Diabetic Peripheral Neuropathy[NCT05558878] | 80 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | |||
| Ambroxol as a Novel Disease Modifying Treatment for Parkinson's Disease Dementia[NCT02914366] | Phase 2 | 55 participants (Actual) | Interventional | 2015-11-30 | Active, not recruiting | ||
| Genotypic Influences on Network Progression in Parkinson's Disease[NCT04228172] | 32 participants (Anticipated) | Observational | 2020-02-24 | Recruiting | |||
| Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy[NCT03950050] | Phase 2 | 40 participants (Actual) | Interventional | 2019-03-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for ambroxol and Parkinson Disease
| Article | Year |
|---|---|
Pharmacological chaperone therapy for the treatment of inborn errors of metabolism
Topics: Ambroxol; Gaucher Disease; Humans; Mutation; Parkinson Disease | 2022 |
Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development.
Topics: Ambroxol; Animals; Anti-Inflammatory Agents; Drug Discovery; Expectorants; Gaucher Disease; Glucosyl | 2018 |
2 trials available for ambroxol and Parkinson Disease
| Article | Year |
|---|---|
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
Topics: Aged; Ambroxol; Brain; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson D | 2019 |
Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
Topics: Aged; Ambroxol; Brain; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson D | 2019 |
Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
Topics: Aged; Ambroxol; Brain; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson D | 2019 |
Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
Topics: Aged; Ambroxol; Brain; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson D | 2019 |
12 other studies available for ambroxol and Parkinson Disease
| Article | Year |
|---|---|
Ambroxol reverses tau and α-synuclein accumulation in a cholinergic N370S GBA1 mutation model.
Topics: alpha-Synuclein; Ambroxol; Cathepsin D; Cells, Cultured; Cholinergic Agents; Glucosylceramidase; Hum | 2022 |
Generation of wild-type rat Glucocerebrosidase homology modeling: Identification of putative interactions site and mechanism for chaperone using combined in-silico and in-vitro studies.
Topics: Ambroxol; Animals; Catalytic Domain; Glucosylceramidase; Molecular Dynamics Simulation; Parkinson Di | 2022 |
Precision Medicine for Parkinson's Disease: Ambroxol for Glucocerebrosidase-Associated Parkinson's Disease, First Trial Completed.
Topics: Ambroxol; Glucosylceramidase; Humans; Mutation; Parkinson Disease; Precision Medicine | 2020 |
Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data.
Topics: Adolescent; Adult; Aged; Ambroxol; Biological Availability; Blood-Brain Barrier; Child; Child, Presc | 2021 |
Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Ambroxol; Cells, Cultured; Enzyme Inhibitors; Female; Gaucher Diseas | 2021 |
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
Topics: Adult; Aged; Aged, 80 and over; Ambroxol; Cells, Cultured; Female; Fibroblasts; Gaucher Disease; Gen | 2014 |
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
Topics: Adult; Aged; Aged, 80 and over; Ambroxol; Cells, Cultured; Female; Fibroblasts; Gaucher Disease; Gen | 2014 |
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
Topics: Adult; Aged; Aged, 80 and over; Ambroxol; Cells, Cultured; Female; Fibroblasts; Gaucher Disease; Gen | 2014 |
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
Topics: Adult; Aged; Aged, 80 and over; Ambroxol; Cells, Cultured; Female; Fibroblasts; Gaucher Disease; Gen | 2014 |
Magic shotgun for Parkinson's disease?
Topics: alpha-Synuclein; Ambroxol; Female; Fibroblasts; Gaucher Disease; Glucosylceramidase; Humans; Male; M | 2014 |
Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.
Topics: Aged; Ambroxol; Antiparkinson Agents; Cells, Cultured; Female; Fibroblasts; Glucosylceramidase; Huma | 2015 |
The contribution of mutant GBA to the development of Parkinson disease in Drosophila.
Topics: Ambroxol; Animals; Disease Models, Animal; Dopaminergic Neurons; Drosophila melanogaster; Endoplasmi | 2016 |
Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models.
Topics: Ambroxol; Animals; Disease Models, Animal; Dopaminergic Neurons; Drosophila melanogaster; Endoplasmi | 2016 |
Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice.
Topics: alpha-Synuclein; Ambroxol; Animals; Brain; Disease Models, Animal; Expectorants; Gaucher Disease; Gl | 2016 |
A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers.
Topics: Adipose Tissue; alpha-Synuclein; Ambroxol; Animals; Autophagy; Cell Differentiation; Dopaminergic Ne | 2017 |